Salvatore Viscomi, M.D. is the CEO and co-founder of Carna Health, a digital health platform innovating CKD population screening, monitoring and care management by leveraging point-of-care testing and AI-driven software. He is also the chief strategy advisor of two healthcare startups, Dama Health and QuantaBrain and an executive advisor to Intellectual Digital, an investment firm based in NYC and London. He previously led a Harvard Stem Cell Institute company’s product line of genetic and biomarker testing. Dr. Viscomi is a practicing physician, instructor and an entrepreneur. He spent 14 years as a member of Harvard Medical School’s faculty and concurrently as a clinician at Brigham and Women’s Hospital. In that capacity, he held various administrative and clinical roles including Director of Admissions of a Harvard Residency Program and Department Chairman.
The consequences for not prioritizing new guidelines for CKD screening have a devastating impact on population health by increasing the global mortality rate and driving higher healthcare costs.
Digital solutions are changing the way CKD is managed. Through enhanced connectivity and personalized care plans tailored to individual patient needs, digital technologies allow patients to take proactive steps in managing CKD.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Unlike inherited genetic predispositions, accumulated genetic changes are the result of environmental influences, such as smoking, chemicals or ultra-violet radiation. A growing body of research links somatic changes to an increased likelihood of blood cancers and cardiovascular disease, both heart disease and stroke.